The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph Nodes
Timothy M. Pawlik(The Ohio State University), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), John F. Thompson(Melanoma Institute Australia), Merrick I. Ross(Johns Hopkins University), Alexander M.M. Eggermont(University Medical Center Utrecht)
Cited by 126
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k